Industries > Pharma > Precision Cancer Diagnostic Test Market Report 2021-2031
Precision Cancer Diagnostic Test Market Report 2021-2031
Forecasts by Category (Cancer Imaging, Molecular Cancer Testing, Tumour Marker Immunoassays, POC Colon Cancer Tests), by Cancer Imaging Test (Computed Tomography, Magnetic Resonance Imaging, Digital & Analog Mammography, Positron Emission Tomography, Digital Breast Tomosynthesis, Molecular Breast Imaging), by Molecular Cancer Testing (Blood-Based Molecular Cancer Tests, HPV Genotyping, Circulating Tumour Cell (CTC) Tests, Next-Generation Sequencing Tests), by End-user (Hospitals, Clinics, Research Institutes) and Regional and Leading National Market Analysis PLUS Analysis of Leading Precision Cancer Diagnostic Test Companies AND COVID-19 Recovery Scenarios
How this report can benefit CEOs and top management personnel to getting an edge in the global competition?
Overall industry success requires an effective balance of productivity in research and development, production efficiency, efficient marketing and distribution and customer service. Including new cancer cases, diagnostic procedures and product demand, across geographic markets, this report presents precision cancer testing indicators from 2021 until 2031 It is also explored in the segment’s activities as a representative group of competitors working in the industry, involving selected companies.
Precision Cancer Diagnostics Test–our new study reveals trends, R&D progress, and predicted revenues
Where is the Precision Cancer Diagnostics Test market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead
Our 449 pages report provides 271 tables, 267 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Precision Cancer Diagnostics Test Market. See how to exploit the opportunities.
This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are following segments, each forecasted at a global and regional level.
How Precision Cancer Diagnostics Test Markets Will Perform in this COVID-19 Pandemic Situation?
In this pandemic situation, the Precision Cancer Diagnostics Test market has become more critical than ever in the last ten years. According to findings just released by the COVID-19 & Cancer Consortium, cancer patients with COVID-19 die three times the rate of non-cancer patients with the disorder. These new data are published in Cancer Discovery by CCC19 at a meeting of the American Association for Cancer Research, and are available to twice as many patients with COVID-19 and show that after 30 days there has been a boost in the mortality rate for cancer patients.
This report says TODAY how the development of cancer diagnostics test is driven by changes in the recession and booming COVID-19 in the next 10 years.
Find out the best-benefit areas for short- to long-term precision cancer diagnostic test and the future prospects. Our new study anticipates global domestic and regional sales. See the results, trends, chances and revenue projections. precision cancer diagnostic tests, there are many opportunities on the growing market. See how opportunities can be used today and how they can succeed.
Discover sales predictions for the world market and submarkets
Market Breakdown by Category (COVID-19 Impact Recovery Analysis Covered)
• Cancer Imaging
• Molecular Cancer Testing
• Tumour Marker Immunoassays
• POC Colon Cancer Tests
Market Breakdown by Cancer Imaging Test (COVID-19 Impact Recovery Analysis Covered)
• Computed Tomography
• Magnetic Resonance Imaging
• Digital & Analog Mammography
• Positron Emission Tomography
• Digital Breast Tomosynthesis
• Molecular Breast Imaging
Market Breakdown by Molecular Cancer Testing (COVID-19 Impact Recovery Analysis Covered)
• Blood-Based Molecular Cancer Tests
• HPV Genotyping
• Circulating Tumour Cell (CTC) Tests
• Next-Generation Sequencing Tests
Market Breakdown by End-User (COVID-19 Impact Recovery Analysis Covered)
• Hospitals
• Clinics
• Research Institutes
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
By Region
• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• Turkey
• Saudi Arabia
• South Africa
• UAE
• Rest of Middle East & Africa
Need industry data? Please contact us today.
Leading companies and the potential for market growth
Overall world revenue for Precision Cancer Diagnostics Test Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Precision Cancer Diagnostics Test Market report helps you?
In summary, our 449-page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Precision Cancer Diagnostics Test Market, forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 14 key national markets – See forecasts for the Precision Cancer Diagnostics Test Markets market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Russia, China, India, and Japan, among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 15 of the major companies involved in the Precision Cancer Diagnostics Test Market.
Abbott Laboratories
Agilent Technologies, Inc.
Becton, Dickinson and Company (BD)
Bio-Rad Laboratories, Inc.
Canon Inc.
Biocept, Inc.
Danaher Corporation (Danaher)
Roche Holding AG (Roche)
ANGLE plc
Epigenomics AG
General Electric Company
Siemens AG
Biomerieux SA
Hologic, Inc.
Myriad Genetics, Inc.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Precision Cancer Diagnostic Test Market Report 2021-2031: Forecasts by Category (Cancer Imaging, Molecular Cancer Testing, Tumour Marker Immunoassays, POC Colon Cancer Tests), by Cancer Imaging Test (Computed Tomography, Magnetic Resonance Imaging, Digital & Analog Mammography, Positron Emission Tomography, Digital Breast Tomosynthesis, Molecular Breast Imaging), by Molecular Cancer Testing (Blood-Based Molecular Cancer Tests, HPV Genotyping, Circulating Tumour Cell (CTC) Tests, Next-Generation Sequencing Tests), by End-user (Hospitals, Clinics, Research Institutes) and Regional and Leading National Market Analysis PLUS Analysis of Leading Precision Cancer Diagnostic Test Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1.1 Scope of the Report
1.2 Why You Should Buy This Report
1.3 How This Report Delivers
1.4 Key Questions Answered by This Analytical Report Include:
1.5 Who is This Report For?
1.6 Methodology
1.6.1 Primary Research
1.6.2 Secondary Research
1.7 Market Evaluation & Forecasting Methodology
1.8 COIVD-19 Impact Recovery Pattern Analysis
1.8.1 V-Shaped Recovery
1.8.2 U-Shaped Recovery
1.8.3 W-Shaped Recovery
1.8.4 L-Shaped Recovery
1.9 Frequently Asked Questions (FAQ)
1.10 Associated Visiongain Reports
1.11 About Visiongain
2 Executive Summary
3 Cancer Diagnostics Overview
3.1 Diagnostics Overview
3.2 Arrays and Microfluidics (LOAC) Technologies
3.2.1 DNA Microarrays
3.2.2 Protein Microarrays
3.2.3 Microfluidics
3.3 Multiplex Conventional Technologies
3.4 Next Generation Sequencing Technology
3.5 Polymerase Chain Reaction (PCR) Technology
3.6 Liquid Biopsy Technologies
3.6.1 Cancer Genomics
3.7 Circulating Tumor Cell Technologies
3.8 CTC Workflow
3.9 Cell Isolation Technologies
3.9.1 The main industry advocate of cell adhesion is Menarini-Silicon Biosystems
3.10 CTC Sample Preparation Technologies
3.11 CTC Downstream Analysis Technologies
3.11.1 Comparison of Liquid Biopsy with Conventional Biopsy
3.12 Cancer Testing
3.13 Avatar-Driven Diagnostic Approaches
4 Market Drivers, Opportunities, and Challenges
4.1 Global Market Drivers
4.1.1 Increasing Global Spending On Oncology
4.1.2 Are significant new product launches propelling the market growth?
4.1.3 How Increased Cancer Patient Access and Value is Impacting Cancer Diagnostics Market?
4.2 What are the Opportunities in the Global Market?
4.2.1 How Modern Technologies will Drive growth for precision cancer diagnostic test market?
4.2.2 Cancer Medicine Will Be Highly Personalized
4.2.3 Innovations in Diagnostic Methods and Technology
4.3 What Are the Challenges in the Global Market?
4.3.1 Promising Diagnostic Tests Ultimately Fail Because Of Inadequate Performance In Real-World
4.3.2 Rigorous Evaluation Of New Tests Has Been A Challenge
4.3.3 Utilization Challenges for Precision Cancer Diagnostic tests
4.3.4 The Cost Associated With Testing For Genomic Alterations And Subsequent Targeted Therapy, Poses Implementation Challenge
5 Global Precision Cancer Diagnostic Test Market Outlook
5.1 Market Analysis by Value (COVID Impact Analysis)
5.1.1 COVID-19 V-Shaped Recovery Analysis
5.1.2 COVID-19 W-Shaped Recovery Analysis
5.1.3 COVID-19 U-Shaped Recovery Analysis
5.1.4 COVID-19 L-Shaped Recovery Analysis
5.1.5 Global market is expected to grow at a CAGR of 9.8% during the forecast period 2021-2031
5.2 Regional Market Analysis (COVID-19 Impact Analysis)
5.2.1 COVID-19 V-Shaped Recovery Analysis
5.2.2 COVID-19 W-Shaped Recovery Analysis
5.2.3 COVID-19 U-Shaped Recovery Analysis
5.2.4 COVID-19 L-Shaped Recovery Analysis
5.2.5 North America is projected to Lead the Global Market During Forecast Period
5.3 Global Market Analysis by Category (COVID-19 Impact Analysis)
5.3.1 COVID-19 V-Shaped Recovery Analysis
5.3.2 COVID-19 W-Shaped Recovery Analysis
5.3.3 COVID-19 U-Shaped Recovery Analysis
5.3.4 COVID-19 L-Shaped Recovery Analysis
5.3.5 Cancer Imaging market is projected to grow at a CAGR of 9.7% and Lead the Market
5.4 Global Market Analysis by Cancer Imaging Test Type (COVID-19 Impact Analysis)
5.4.1 COVID-19 V-Shaped Recovery Analysis
5.4.2 COVID-19 W-Shaped Recovery Analysis
5.4.3 COVID-19 U-Shaped Recovery Analysis
5.4.4 COVID-19 L-Shaped Recovery Analysis
5.4.5 Magnetic Resonance Imaging Segment is Projected to Grow at the Fastest Rate
5.5 Global Market Analysis by Molecular Cancer Testing Type (COVID-19 Impact Analysis)
5.5.1 COVID-19 V-Shaped Recovery Analysis
5.5.2 COVID-19 W-Shaped Recovery Analysis
5.5.3 COVID-19 U-Shaped Recovery Analysis
5.5.4 COVID-19 L-Shaped Recovery Analysis
5.5.5 HPV Genotyping Segment is Projected to be the Fastest Growing Segment in the Market
5.6 Global Market Analysis by End-User (COVID-19 Impact Analysis)
5.6.1 COVID-19 V-Shaped Recovery Analysis
5.6.2 COVID-19 W-Shaped Recovery Analysis
5.6.3 COVID-19 U-Shaped Recovery Analysis
5.6.4 COVID-19 L-Shaped Recovery Analysis
5.6.5 Hospitals Emerged as the Major User and is Projected to Maintain the Dominance
6 North America Precision Cancer Diagnostic Test Market Outlook
6.1 North America Market Analysis by Value (COVID-19 Impact Analysis)
6.2 North America Market Analysis by Country (COVID-19 Impact Analysis)
6.3 US Market Analysis
6.3.1 US Cancer Snapshot 2019
6.3.2 US Market Analysis by Value (COVID-19 Impact Analysis)
6.3.3 In 2020, an estimated 1,806,590 new cases of cancer will be diagnosed in the United States
6.4 Canada Market Analysis
6.4.1 Canada Cancer Snapshot 2019
6.4.2 Canada Market Analysis by Value (COVID-19 Impact Analysis)
6.4.3 It is estimated that in 2020, 115,800 Canadian men will be diagnosed with cancer
6.5 North America Market Analysis by Category (COVID-19 Impact Analysis)
6.6 North America Market Analysis by Cancer Imaging Test Type (COVID-19 Impact Analysis)
6.7 North America Market Analysis by Molecular Cancer Testing Type (COVID-19 Impact Analysis)
6.8 North America Market Analysis by End-User (COVID-19 Impact Analysis)
7 Europe Precision Cancer Diagnostic Test Market Outlook
7.1 Europe Market Analysis by Value (COVID-19 Impact Analysis)
7.2 Europe Market Analysis by Country (COVID-19 Impact Analysis)
7.3 Russia Market Analysis
7.3.1 Russia Cancer Snapshot 2019
7.3.2 Russia Market Analysis by Value (COVID-19 Impact Analysis)
7.3.3. In Russia, the overall risk of dying from cancer is about 60%,
7.4 Germany Market Analysis
7.4.1 Germany Cancer Snapshot 2019
7.4.2 Germany Market Analysis by Value (COVID-19 Impact Analysis)
7.4.3 By 2030, prostate cancer will be the most common malignancy, surpassing breast cancer
7.5 UK Market Analysis
7.5.1 UK Cancer Snapshot 2019
7.5.2 UK Market Analysis by Value (COVID-19 Impact Analysis)
7.5.3 By 2035, the number of new cancer cases is projected to rise to over half a million a year
7.6 France Market Analysis
7.6.1 France Cancer Snapshot 2019
7.6.2 France Market Analysis by Value (COVID-19 Impact Analysis)
7.6.3 One in two men and one in three women will be diagnosed with cancer
7.7 Italy Market Analysis
7.7.1 Italy Cancer Snapshot 2019
7.7.2 Italy Market Analysis by Value (COVID-19 Impact Analysis)
7.7.3 In Italy, in 2018, over 369,000 new cases of cancer were diagnosed
7.8 Rest of Europe Market Analysis by Value (COVID-19 Impact Analysis)
7.9 Europe Market Analysis by Category (COVID-19 Impact Analysis)
7.10 Europe Market Analysis by Cancer Imaging Test Type (COVID-19 Impact Analysis)
7.11 Europe Market Analysis by Molecular Cancer Testing Type (COVID-19 Impact Analysis)
7.12 Europe Market Analysis by End-User (COVID-19 Impact Analysis)
8 Asia-Pacific Precision Cancer Diagnostic Test Market Outlook
8.1 Asia-Pacific Market Analysis by Value (COVID-19 Impact Analysis)
8.2 Asia-Pacific Market Analysis by Country (COVID-19 Impact Analysis)
8.3 Japan Market Analysis
8.3.1 Japan Cancer Snapshot 2019
8.3.2 Japan Market Analysis by Value (COVID-19 Impact Analysis)
8.3.3 Cancer is the leading cause of death in Japan for more than 30 years
8.4 China Market Analysis
8.4.1 China Cancer Snapshot 2019
8.4.2 China Market Analysis by Value (COVID-19 Impact Analysis)
8.4.3 China is undergoing the cancer transition stage where the cancer spectrum is changing from developing country to developed country
8.5 India Market Analysis
8.5.1 India Cancer Snapshot 2019
8.5.2 India Market Analysis by Value (COVID-19 Impact Analysis)
8.5.3 Cancer is emerging as a major public health concern in India
8.6 Korea Market Analysis
8.6.1 Korea Cancer Snapshot 2019
8.6.2 Korea Market Analysis by Value (COVID-19 Impact Analysis)
8.6.3 In 2018, over 240,000 patients were newly diagnosed with cancer in Korea
8.7 Australia Market Analysis
8.7.1 Australia Cancer Snapshot 2019
8.7.2 Australia Market Analysis by Value (COVID-19 Impact Analysis)
8.7.3 Around 30 years ago, about 5 in 10 people survived for at least 5 years after their cancer diagnosis
8.8 Rest of Asia-Pacific Market Analysis by Value (COVID-19 Impact Analysis)
8.9 Asia-Pacific Market Analysis by Category (COVID-19 Impact Analysis)
8.10 Asia-Pacific Market Analysis by Cancer Imaging Testing Type (COVID-19 Impact Analysis)
8.11 Asia-Pacific Market Analysis by Molecular Cancer Testing Type (COVID-19 Impact Analysis)
8.12 Asia-Pacific Market Analysis by End-User (COVID-19 Impact Analysis)
9 LAMEA Precision Cancer Diagnostic Test Market Outlook
9.1 LAMEA Market Analysis by Value (COVID-19 Impact Analysis)
9.2 LAMEA Market Analysis by Country (COVID-19 Impact Analysis)
9.3 Brazil Market Analysis
9.3.1 Brazil Cancer Snapshot 2019
9.3.2 Brazil Market Analysis by Value (COVID-19 Impact Analysis)
9.3.3 It is estimated that more than 600,000 new cases of cancer will be reported in Brazil
9.4 Saudi Arabia Market Analysis
9.4.1 Saudi Arabia Cancer Snapshot 2019
9.4.2 Saudi Arabia Market Analysis by Value (COVID-19 Impact Analysis)
9.4.3 The percentage of deaths due to cancer decreased after 70 years of age in Saudi Arabia population
9.5 South Africa Market Analysis
9.5.1 South Africa Cancer Snapshot 2019
9.5.2 South Africa Market Analysis by Value (COVID-19 Impact Analysis)
9.5.3 Lung cancer, cervical cancer, and oesophageal cancer are the three deadliest cancers in South Africa
9.6 Mexico Market Analysis
9.6.1 Mexico Cancer Snapshot 2019
9.6.2 Mexico Market Analysis by Value (COVID-19 Impact Analysis)
9.6.3 The main public health problems in the country are chronic degenerative diseases
9.7 UAE Market Analysis
9.7.1 UAE Cancer Snapshot 2019
9.7.2 UAE Market Analysis by Value (COVID-19 Impact Analysis)
9.7.3 The UAE is determined to bring down cancer fatalities by nearly 18 per cent by 2021
9.8 Rest of LAMEA Market Analysis by Value (COVID-19 Impact Analysis)
9.9 LAMEA Market Analysis by Category (COVID-19 Impact Analysis)
9.10 LAMEA Market Analysis by Cancer Imaging (COVID-19 Impact Analysis)
9.11 LAMEA Market Analysis by Molecular Cancer Testing Type (COVID-19 Impact Analysis)
9.12 LAMEA Market Analysis by End-User (COVID-19 Impact Analysis)
10 Next Generation Cancer Diagnostics: Key Initiatives and Programs
10.1 Blood Profiling Atlas
10.1.1 Cancer-ID
10.1.2 Cancer Moon Shots
10.1.3 China Precision Medicine Initiative
10.1.4 ClinGen
10.2 CTC Trap Consortium
10.2.1 Early Cancer Detection Consortium
10.2.2 EpiFemCare
10.2.3 France Genomic Medicine Plan
10.2.4 Friends of Cancer Research Project
10.3 Human Cell Atlas
10.3.1 Immunomonitor Consortium
10.3.2 Integration of Imaging and Fluid-Based Tumour Monitoring
10.3.3 Liquid Biopsies and Imaging for Improved Cancer Care
10.3.4 Million Veteran Program
10.3.5 MedSeq
10.4 Next-Generation Single-Cell Analysis Program
10.4.1 Population Sequencing Projects
10.4.2 Precancer Atlas
10.4.3 Precision Medicine Initiative
10.4.4 Prompt
10.4.5 QuIP Project
10.5 Single-Cell Proteomics and Lipidomics Project
10.5.1 TopMed
10.5.2 Treehouse Childhood Cancer Initiative
10.5.3 Very Rare Cancer Consortium
10.6 Worldwide Innovative Networking (WIN) Consortium
10.6.1 Single-Cell Research
10.6.2 Cambridge Single-Cell Analysis Core Facility
10.6.3 Harvard Medical School Single-Cell Core
10.6.4 Mayo Medical Genome Facility
10.6.5 National Center for Single-Cell Biology
10.6.6 Single-Cell Analysis Core
10.6.7 UC San Francisco Single-Cell Analysis Center
10.6.8 Population Sequencing Programs
11 Leading Company Profiles
11.1 Abbott Laboratories Company
11.1.1 Company Information
11.1.2 Company Overview
11.1.3 Company Financial Profile
11.1.4 Company Product Offerings
11.1.5 Company Recent Developments
11.2 Agilent Technologies, Inc Company
11.2.1 Company Information
11.2.2 Company Overview
11.2.3 Company Financial Profile
11.2.4 Company Product Offerings
11.2.5 Company Recent Developments
11.3 Becton, Dickinson and Company
11.3.1 Company Information
11.3.2 Company Overview
11.3.3 Company Financial Profile
11.3.4 Company Product Offerings
11.3.5 Company Recent Developments
11.4 Bio-Rad Laboratories, Inc. Company
11.4.1 Company Information
11.4.2 Company Overview
11.4.3 Company Financial Profile
11.4.4 Company Product Offerings
11.4.5 Company Recent Developments
11.5 Canon Medical Systems Corporation Company
11.5.1 Company Information
11.5.2 Company Overview
11.5.3 Company Financial Profile
11.5.4 Company Product Offerings
11.5.5 Company Recent Developments
11.6 Biocept, Inc Company
11.6.1 Company Information
11.6.2 Company Overview
11.6.3 Company Financial Profile
11.6.4 Company Product Offerings
11.6.5 Company Recent Developments
11.7 Danaher Corporation Company
11.7.1 Company Information
11.7.2 Company Overview
11.7.3 Company Financial Profile
11.7.4 Company Product Offerings
11.7.5 Company Recent Developments
11.8 Roche Holding AG Company
11.8.1 Company Information
11.8.2 Company Overview
11.8.3 Company Financial Profile
11.8.4 Company Product Offerings
11.8.5 Company Recent Developments
11.9 Angle plc Company
11.9.1 Company Information
11.9.2 Company Overview
11.9.3 Company Financial Profile
11.9.4 Company Product Offerings
11.9.5 Company Recent Developments
11.10 Epigenomics AG Company
11.10.1 Company Information
11.10.2 Company Overview
11.10.3 Company Financial Profile
11.10.4 Company Product Offerings
11.10.5 Company Recent Developments
11.11 General Electric Company Company
11.11.1 Company Information
11.11.2 Company Overview
11.11.3 Company Financial Profile
11.11.4 Company Product Offerings
11.11.5 Company Recent Developments
11.12 Siemens AG Company
11.12.1 Company Information
11.12.2 Company Overview
11.12.3 Company Financial Profile
11.12.4 Company Product Offerings
11.12.5 Company Recent Developments
11.13 Biomerieux SA Company
11.13.1 Company Information
11.13.2 Company Overview
11.13.3 Company Financial Profile
11.13.4 Company Product Offerings
11.13.5 Company Recent Developments
11.14 Hologic, Inc Company
11.14.1 Company Information
11.14.2 Company Overview
11.14.3 Company Financial Profile
11.14.4 Company Product Offerings
11.14.5 Company Recent Developments
11.15 Myriad Genetics, Inc Company
11.15.1 Company Information
11.15.2 Company Overview
11.15.3 Company Financial Profile
11.15.4 Company Product Offerings
11.15.5 Company Recent Developments
11.16 Other Leading Companies in the Market
12 Conclusion & Recommendations
12.1 Recommendations for Clinicians
12.2 Recommendations for Policy Makers
13 Glossary
List of Figure
Figure 5.1 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 5.2 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 5.3 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 5.4 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 5.5 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 6.1 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 6.2 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 6.3 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 6.4 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 6.5 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 6.6 North America Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 6.7 North America Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 6.8 North America Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 6.9 North America Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 6.10 North America Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 6.11 US Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 6.12 Canada Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 6.13 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 6.14 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 6.15 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 6.16 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 6.17 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 6.18 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 6.19 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 6.20 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 6.21 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 6.22 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 6.23 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 6.24 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 6.25 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 6.26 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 6.27 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 6.28 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 6.29 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 6.30 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 6.31 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 6.32 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 7.1 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 7.2 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 7.3 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 7.4 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 7.5 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 7.6 Europe Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 7.7 Europe Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 7.8 Europe Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 7.9 Europe Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 7.10 Europe Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 7.11 Russia Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 7.12 Germany Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 7.13 UK Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 7.14 France Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 7.15 Italy Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 7.16 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 7.17 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 7.18 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 7.19 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 7.20 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 7.21 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 7.22 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 7.23 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 7.24 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 7.25 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 7.26 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 7.27 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 7.28 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 7.29 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 7.30 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 7.31 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 7.32 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 7.33 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 7.34 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 7.35 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 8.1 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 8.2 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 8.3 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 8.4 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 8.5 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 8.6 Asia-Pacific Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 8.7 Asia-Pacific Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 8.8 Asia-Pacific Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 8.9 Asia-Pacific Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 8.10 Asia-Pacific Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 8.11 Japan Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 8.12 China Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 8.13 India Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 8.14 Korea Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 8.15 Australia Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 8.16 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 8.17 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 8.18 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 8.19 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 8.20 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 8.21 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 8.22 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 8.23 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 8.24 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 8.25 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 8.26 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 8.27 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 8.28 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 8.29 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 8.30 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 8.31 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 8.32 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 8.33 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 8.34 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 8.35 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 9.1 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 9.2 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 9.3 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 9.4 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 9.5 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 9.6 LAMEA Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 9.7 LAMEA Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 9.8 LAMEA Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 9.9 LAMEA Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 9.10 LAMEA Precision Cancer Diagnostic Test Market by Country Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 9.11 Brazil Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 9.12 Saudi Arabia Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 9.13 South Africa Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 9.14 Mexico Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 9.15 UAE Cancer Snapshot 2019 (Population, Total Cases, Deaths, %)
Figure 9.16 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 9.17 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 9.18 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 9.19 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 9.20 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 9.21 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 9.22 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 9.23 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 9.24 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 9.25 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 9.26 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 9.27 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 9.28 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 9.29 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 9.30 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 9.31 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (Pre-COVID-19 Analysis)
Figure 9.32 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 V-Shaped Recovery)
Figure 9.33 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 W-Shaped Recovery)
Figure 9.34 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 U-Shaped Recovery)
Figure 9.35 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %) (COVID-19 L-Shaped Recovery)
Figure 11.1 Abbott Laboratories Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.2 Abbott Laboratories Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.3 Abbott Laboratories Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.4 Abbott Laboratories Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.5 Agilent Technologies, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.6 Agilent Technologies, Inc: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.7 Agilent Technologies, Inc: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.8 Agilent Technologies, Inc: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.9 Becton, Dickinson and Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.10 Becton, Dickinson and Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.11 Becton, Dickinson and Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.12 Becton, Dickinson and Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.13 Bio-Rad Laboratories, Inc. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.14 Bio-Rad Laboratories, Inc. Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.15 Bio-Rad Laboratories, Inc. Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.16 Bio-Rad Laboratories, Inc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.17 Canon Medical Sys Corp Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.18 Canon Medical Sys Corp. Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.19 Canon Medical Sys Corp. Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.20 Canon Medical Sys Corp. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.21 Biocept, Inc. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.22 Biocept Inc. Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.23 Biocept Inc. Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.24 Biocept Inc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.25 Danaher Corporation Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.26 Danaher Corporation Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.27 Danaher Corporation Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.28 Danaher Corporation Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.29 Roche Holding AG. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.30 Roche Holding AG Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.31 Roche Holding AG. Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.32 Roche Holding AG. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.33 Angle plc Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.34 Angle plc Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.35 Angle plc. Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.36 Angle plc. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.37 Epigenomics AG. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.38 Epigenomics AG. Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.39 Epigenomics AG. Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.40 Epigenomics AG. Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.41 General Electric Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.42 General Electric Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.43 General Electric Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.44 General Electric Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.45 Siemens AG Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.46 Siemens AG Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.47 Siemens AG Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.48 Siemens AG Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.49 Biomérieux SA Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.50 Kkk. Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.51 Biomérieux SA Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.52 Biomérieux SA Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.53 Hologic, Inc. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.54 Hologic, Inc Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.55 Hologic, Inc Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.56 Hologic, Inc Company: Company Net Income/Loss 2015-2019 (US$ Mn)
Figure 11.57 Myriad Genetics, Inc Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Figure 11.58 Myriad Genetics, Inc Company: Company Operating Income 2015-2019 (US$ Mn)
Figure 11.59 Myriad Genetics, Inc. Company: Company EBITDA 2015-2019 (US$ Mn)
Figure 11.60 Myriad Genetics, Inc Company: Company Net Income/Loss 2015-2019 (US$ Mn)
List of Tables
Table 2.1 Global Precision Cancer Diagnostic Test Market Summary Table
Table 3.1 Diagnostic Market Segments
Table 3.2 Next Generation Diagnostics: Key Analysis Platforms
Table 3.3 Analysis Platforms and Biomarker Types
Table 3.4 DNA Microarray Technologies in Cancer Diagnostics
Table 3.5 Design Features of Protein Microarray Technologies
Table 3.6 Microfluidic LOAC Types Used in Cancer Diagnostics
Table 3.7 Advanced Sequencing Technologies
Table 3.8 Illumina Next Generation Sequencing Workflow
Table 3.9 Thermo Fisher Scientific’s Next Generation Sequencing Workflow
Table 3.10 Main Ingredients of PCR Technology
Table 3.11 PCR Process
Table 3.12 Advantages of Droplet Digital PCR for Single-Cell Analysis
Table 3.13 Liquid Biopsy Biomarker Classes
Table 3.14 Cancer Genomic Sequencing and Liquid Biopsy
Table 3.15 Single-Cell Analysis to Identify Cancer Driver Mutations
Table 3.16 Genomics-Based Oncology Workflow
Table 3.17 Unique Challenges: CTC Capture and Analysis
Table 3.18 CTC Workflow
Table 3.19 Cell Differentiators
Table 3.20 Cell Isolation Technologies
Table 3.21 CTC Sample Preparation Technologies
Table 3.22 Single-Cell Analysis Technologies
Table 3.23 Estimated Annual Solid Biopsy Procedures, U.S., Selected Cancers
Table 3.24 Main Risks of Needle-Based Tissue Biopsies
Table 3.25 Factors in Tissue Biopsy
Table 3.26 Approaches to Avatar-Driven Cancer Diagnostics
Table 5.1 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 5.2 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 5.3 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 5.4 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 5.5 Global Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 5.6 Global Precision Cancer Diagnostic Test Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 5.7 Global Precision Cancer Diagnostic Test Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 5.8 Global Precision Cancer Diagnostic Test Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 5.9 Global Precision Cancer Diagnostic Test Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 5.10 Global Precision Cancer Diagnostic Test Market by Region Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 5.11 Global Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 5.12 Global Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 5.13 Global Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 5.14 Global Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 5.15 Global Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 5.16 Global Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 5.17 Global Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 5.18 Global Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 5.19 Global Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 5.20 Global Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 5.21 Global Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 5.22 Global Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 5.23 Global Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 5.24 Global Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 5.25 Global Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 5.26 Global Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 5.27 Global Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 5.28 Global Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 5.29 Global Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 5.30 Global Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 6.1 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 6.2 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 6.3 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 6.4 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 6.5 North America Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 6.6 US Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 6.7 US Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 6.8 US Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 6.9 US Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 6.10 US Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 6.11 Canada Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 6.12 Canada Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 6.13 Canada Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 6.14 Canada Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 6.15 Canada Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 6.16 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 6.17 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 6.18 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 6.19 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 6.20 North America Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 6.21 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 6.22 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 6.23 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 6.24 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 6.25 North America Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 6.26 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 6.27 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 6.28 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 6.29 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 6.30 North America Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 6.31 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 6.32 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 6.33 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 6.34 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 6.35 North America Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.1 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.2 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.3 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.4 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.5 Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.6 Russia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.7 Russia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.8 Russia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.9 Russia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.10 Russia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.11 Germany Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.12 Germany Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.13 Germany Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.14 Germany Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.15 Germany Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.16 UK Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.17 UK Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.18 UK Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.19 UK Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.20 UK Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.21 France Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.22 France Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.23 France Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.24 France Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.25 France Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.26 Italy Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.27 Italy Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.28 Italy Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.29 Italy Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.30 Italy Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.31 Rest of Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.32 Rest of Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.33 Rest of Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.34 Rest of Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.35 Rest of Europe Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.36 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.37 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.38 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.39 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.40 Europe Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.41 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.42 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.43 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.44 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.45 Europe Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.46 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.47 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.48 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.49 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.50 Europe Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 7.51 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 7.52 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 7.53 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 7.54 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 7.55 Europe Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 8.1 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 8.2 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 8.3 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 8.4 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 8.5 Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 8.6 Japan Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 8.7 Japan Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 8.8 Japan Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 8.9 Japan Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 8.10 Japan Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 8.11 China Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 8.12 China Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 8.13 China Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 8.14 China Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 8.15 China Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 8.16 India Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 8.17 India Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 8.18 India Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 8.19 India Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 8.20 India Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 8.21 Korea Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 8.22 Korea Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 8.23 Korea Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 8.24 Korea Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 8.25 Korea Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 8.26 Australia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 8.27 Australia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 8.28 Australia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 8.29 Australia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 8.30 Australia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 8.31 Rest of Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 8.32 Rest of Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 8.33 Rest of Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 8.34 Rest of Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 8.35 Rest of Asia-Pacific Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 8.36 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 8.37 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 8.38 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 8.39 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 8.40 Asia-Pacific Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 8.41 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 8.42 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 8.43 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 8.44 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 8.45 Asia-Pacific Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 8.46 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 8.47 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 8.48 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 8.49 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 8.50 Asia-Pacific Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 8.51 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 8.52 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 8.53 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 8.54 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 8.55 Asia-Pacific Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 9.1 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 9.2 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 9.3 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 9.4 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 9.5 LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 9.6 Brazil Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 9.7 Brazil Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 9.8 Brazil Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 9.9 Brazil Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 9.10 Brazil Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 9.11 Saudi Arabia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 9.12 Saudi Arabia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 9.13 Saudi Arabia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 9.14 Saudi Arabia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 9.15 Saudi Arabia Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 9.16 South Africa Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 9.17 South Africa Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 9.18 South Africa Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 9.19 South Africa Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 9.20 South Africa Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 9.21 Mexico Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 9.22 Mexico Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 9.23 Mexico Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 9.24 Mexico Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 9.25 Mexico Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 9.26 UAE Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 9.27 UAE Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 9.28 UAE Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 9.29 UAE Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 9.30 UAE Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 9.31 Rest of LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 9.32 Rest of LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 9.33 Rest of LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 9.34 Rest of LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 9.35 Rest of LAMEA Precision Cancer Diagnostic Test Market by Value Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 9.36 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 9.37 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 9.38 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 9.39 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 9.40 LAMEA Precision Cancer Diagnostic Test Market by Category Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 9.41 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 9.42 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 9.43 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 9.44 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 9.45 LAMEA Precision Cancer Imaging Test Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 9.46 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 9.47 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 9.48 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 9.49 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 9.50 LAMEA Precision Molecular Cancer Testing Market by Type Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 9.51 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (Pre-COVID-19 Analysis)
Table 9.52 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 V-Shaped Recovery)
Table 9.53 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 W-Shaped Recovery)
Table 9.54 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 U-Shaped Recovery)
Table 9.55 LAMEA Precision Cancer Diagnostic Test Market by End-User Forecast 2021-2031 (US$ million, AGR %, CAGR %) (COVID-19 L-Shaped Recovery)
Table 10.1 R &D: Next Generation Cancer Diagnostics
Table 10.2 Single-Cell Core Research Facilities
Table 10.3 Population Sequencing Projects
Table 11.1 Abbott Laboratories: Company Information
Table 11.2 Abbott Laboratories Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Table 11.3 Abbott Laboratories: Company Product and Service Offerings
Table 11.4 Abbott Laboratories: Company Recent Developments till Oct,2020
Table 11.5 Agilent Technologies, Inc: Company Information
Table 11.6 Agilent Technologies, Inc: Company Revenue 2015-2019 (US$Mn, AGR %)
Table 11.7 Agilent Technologies, Inc: Company Product and Service Offerings
Table 11.8 Agilent Technologies, Inc: Company Recent Developments till Oct,2020
Table 11.9 Becton, Dickinson and Company: Company Information
Table 11.10 Becton, Dickinson and Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Table 11.11 Becton, Dickinson and Company: Company Product and Service Offerings
Table 11.12 Becton, Dickinson and Company: Company Recent Developments till Oct,2020
Table 11.13 Bio-Rad Laboratories, Inc: Company Information
Table 11.14 Bio-Rad Laboratories, Inc. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Table 11.15 Bio-Rad Laboratories, Inc: Company Product and Service Offerings
Table 11.16 Bio-Rad Laboratories, Inc: Company Recent Developments till Oct,2020
Table 11.17 Canon Medical Sys Corp: Company Information
Table 11.18 Canon Medical Sys Corp Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Table 11.19 Canon Medical Sys Corp: Company Product and Service Offerings
Table 11.20 Canon Medical Sys Corp: Company Recent Developments till Oct,2020
Table 11.21 Biocept, Inc: Company Information
Table 11.22 Biocept Inc. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Table 11.23 Biocept Inc: Company Product and Service Offerings
Table 11.24 Biocept Inc: Company Recent Developments till Oct,2020
Table 11.25 Danaher Corporation: Company Information
Table 11.26 Danaher Corporation Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Table 11.27 Danaher Corporation: Company Product and Service Offerings
Table 11.28 Danaher Corporation: Company Recent Developments till Oct,2020
Table 11.29 Roche Holding AG: Company Information
Table 11.30 Roche Holding AG. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Table 11.31 Roche Holding AG: Company Product and Service Offerings
Table 11.32 Roche Holding AG: Company Recent Developments till Oct,2020
Table 11.33 Angle plc: Company Information
Table 11.34 Angle plc Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Table 11.35 Angle plc: Company Product and Service Offerings
Table 11.36 Angle plc: Company Recent Developments till Oct,2020
Table 11.37 Epigenomics AG: Company Information
Table 11.38 Kkk Epigenomics AG. Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Table 11.39 Epigenomics AG: Company Product and Service Offerings
Table 11.40 Epigenomics AG: Company Recent Developments till Oct,2020
Table 11.41 General Electric Company: Company Information
Table 11.43 General Electric Company: Company Product and Service Offerings
Table 11.44 General Electric Company: Company Recent Developments till Oct,2020
Table 11.45 Siemens AG: Company Information
Table 11.46 Siemens AG Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Table 11.47 Siemens AG: Company Product and Service Offerings
Table 11.48 Siemens AG: Company Recent Developments till Oct,2020
Table 11.49 Biomérieux SA: Company Information
Table 11.50 Biomérieux SA Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Table 11.51 Biomérieux SA: Company Product and Service Offerings
Table 11.52 Biomérieux SA: Company Recent Developments till Oct,2020
Table 11.53 Hologic, Inc: Company Information
Table 11.54 Hologic, Inc Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Table 11.55 Hologic, Inc: Company Product and Service Offerings
Table 11.56 Hologic, Inc: Company Recent Developments till Oct,2020
Table 11.57 Myriad Genetics, Inc: Company Information
Table 11.58 Myriad Genetics, Inc Company: Company Revenue 2015-2019 (US$Mn, AGR %)
Table 11.59 Myriad Genetics, Inc: Company Product and Service Offerings
Table 11.60 Myriad Genetics, Inc: Company Recent Developments till Oct,2020
Table 11.61 List of Other Leading Companies in the Global Market
Abbott Laboratories
Agilent Technologies, Inc.
ANGLE plc
Becton, Dickinson and Company (BD)
Bio-Rad Laboratories, Inc.
Biocept, Inc.
Biomerieux SA
Canon Inc.
Danaher Corporation (Danaher)
Epigenomics AG
General Electric Company
Hologic, Inc.
Myriad Genetics, Inc.
Roche Holding AG (Roche)
Siemens AG
List of Other Companies Mentioned in the Report
Abbott Laboratories
Agilent Technologies, Inc.
Angle plc
Apellis Pharmaceuticals
Baxter InternationalHealth care company
Becton Dickinson and Company
BGI Group
Bio-Rad Laboratories, Inc.
Biocartis N.V.
Biocept, Inc.
bioMérieux SA
Biotechnology company
Boston Scientific
Canon Medical Systems Corporation
Cardinal Health
Celyad Oncology
Cynvenio Biosystems, Inc.
Danaher Corporation
DePuy Synthes Companies
Edwards Lifesciences
Epigenomics AG
Exact Sciences Corporation
Exosome Diagnostics, Inc.
Foundation Medicine, Inc.
Freenome, Inc.
Galápagos NV
General Electric Company
GENEWIZ, Inc.
Genomic Health, Inc.
Globus Medical Inc
Hologic, Inc.
Illumina, Inc.
Medtronic Medical device company
Menarini Silicon Biosystems SpA
Myriad Genetics, Inc.
NanoString Technologies, Inc.
Nobel Biocare
Ortho Clinical Diagnostics
Orthofix
Pacific Biosciences
QIAGEN N.V.
Randox Laboratories Ltd.
Roche Holding AG
Royal Philips N.V.
Sartorius Stedim Biotech
Siemens AG
Smith & Nephew
Stryker Corporation
Thermo Fisher Scientific
Vela Diagnostics
Zimmer Biomet
Zymergen, Inc.
List of Organizations Mentioned in the Report
Acoustic Neuroma Association
Acoustic Neuroma Association of Australia
Acoustic Neuroma Association of Canada
American Association for Cancer Research
American Bone Marrow Donor Registry
American Brain Tumor Association
American Cancer Society
American Cancer Society (ACS)
American Childhood Cancer Organization
American College of Radiation Oncology
American Gastroenterological Association
American Head and Neck Society
American Society for Radiation Oncology
American Society of Clinical Oncology
American Society of Pediatric Hematology/Oncology
Aplastic Anemia and MDS International Foundation
Armenian Association of Hematology and Oncology
Asian Society for Neuro-Oncology
Associação Brasiliense de Apoio ao Paciente com Câncer
Association for International Cancer Research
Association for Multiple Endocrine Neoplasia Disorders
Association for the Study of Lung Cancer
Association Francaise de La maladie de Fanconi
Association of Cancer Online Resources
Association of Cancer Physicians
Association of Community Cancer Centers
Association of European Cancer Leagues
Association of Gynecologic Oncologists of India
Association of Oncology Social Work
Association of Parents of Children with Cancer
Association of Pediatric Hematology / Oncology Nurses
Association of Population-based Cancer Registries in Germany
Association of Radiation Oncologists of India
Australasian Association of Cancer Registries
Australasian Lung Cancer Trials Group
Australian and New Zealand Children's Haematology/Oncology Group
Australian Association of Smoking Cessation Professionals
Australian Capital Territory Cancer Registry
Australian Cervical Cancer Foundation
Australian Familial Pancreatic Cancer Cohort
Australian Mesothelioma Registry
Australian Oncology Social Work Inc.
Australian Prostate Cancer Research
Australian Society of Gynaecologic Oncologists
Australian Thyroid Foundation
Austrian Cancer Society
Avon Breast Cancer Crusade
Bangladesh Cancer Society
BANO overview (UICC)
Barbados Cancer Society
BASO ~ The Association for Cancer Surgery
Bill & Melinda Gates Foundation
Biomedical Advanced Research and Development Authority (BARDA)
Cancer Research UK
Defense Advanced Research Projects Agency
Friedrich-Loeffler-Institute
Institute of Immunology of the Centre de Recherche Public-Santé (CRP)
Karolinska Institutet
University of Pennsylvania (Penn)
World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Precision Cancer Diagnostic Test Market Report 2021-2031Related reports
Cancer Biologics Market Report 2021-2031
The global demand for cancer biologics is expected to expand significantly over the projected period, owing to the expanded acceptance...Full DetailsPublished: 04 February 2021Cancer Supportive Care Drugs Market Report 2020-2030
Cancer has been primarily leading causes of death worldwide and most treatments for cancer come with various side effects such...
Full DetailsPublished: 01 January 1970Cancer Diagnostics Market Report 2021-2031
Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel...Full DetailsPublished: 14 April 2021Biologics Market Report 2020-2030
Over the years, the global biologics market has increased and estimates are made that in the next five years i.e....Full DetailsPublished: 04 August 2020Ovarian Cancer Drugs Market Report 2020-2030
Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
...Full DetailsPublished: 01 January 1970Cancer Tumour Profiling Market Report 2020-2030
The global cancer tumor profiling market is driven by the adoption of advanced cancer profiling methods by oncologists to diagnose,...
Full DetailsPublished: 01 January 1970Cancer Biologics Therapies Market Report 2021-2031
The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or...Full DetailsPublished: 01 April 2021Bile Duct Cancer Drugs Market Report to 2031
Where is the Global Bile Duct Cancer Drug market heading? If you are involved in this sector you must read...
Full DetailsPublished: 01 January 1970Global Biosimilars and Follow-On Biologics Market 2020-2030
The global biosimilars and follow-on biologics market is estimated to have reached $19.87bn in 2019 and expected to grow at...
Full DetailsPublished: 30 April 2020Urothelial Cancer Drugs Market Report 2021-2031
Where the Urothelial Cancer Drugs market is heading? If you are involved in this industry you must read this newly...
Full DetailsPublished: 01 January 1970
Download sample pages
Complete the form below to download your free sample pages for Precision Cancer Diagnostic Test Market Report 2021-2031Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Latest Pharma news
Visiongain Publishes Bioreactors Market Report 2023-2033
The global Bioreactors market was estimated to be valued at US$ 9,9770.0 million in 2023 and is expected to register a CAGR of 12.2% from 2023 to 2033.
29 September 2023
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
27 September 2023
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
25 September 2023
Visiongain Publishes Anti-infective Vaccines Market Report 2023-2033
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
21 September 2023